SUZUKEN (9987) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The first quarter of the fiscal year ending March 2027 resulted in higher revenue but lower earnings, with the most important issue being a structural decline in profitability whereby revenue growth failed to translate into earnings growth. Revenue increased to ¥6,289.6B (+6.1% year on year), securing higher sales, but Operating Income declined to ¥41.9B (down 25.0%), Ordinary Income to ¥50.7B (down 12.3%), and Net Income attributable to owners of the parent to ¥33.8B (down 10.6%), with declines across all profit indicators. The primary factor was deterioration in the gross profit margin of the core Pharmaceutical Wholesale Business. In addition to limited growth in gross profit relative to revenue growth, losses in the Digital Business and Regional Medical and Nursing Care Support segments expanded, diluting the company-wide margin.

Factors Affecting Business Performance

【Revenue】Revenue of ¥6,289.6B represented a year-on-year +6.1% increase, led by the core Pharmaceutical Wholesale Business (96.7% of revenue), which grew +6.3%. Logistics (+2.9%) and the Digital Business (+33.3%, small scale) also contributed to revenue growth, while Regional Medical and Nursing Care Support declined by △1.7%, and Other Related Businesses decreased modestly by △2.2%.

【Profit and Loss】Gross profit was ¥433.5B, up +0.2% year on year and virtually flat, while the gross profit margin declined to 6.9% from the previous year. Although SG&A expenses were ¥391.6B (SG&A ratio: 6.2%) and efficiency improvements progressed, these were insufficient to absorb the deterioration in the gross profit margin. Operating Income declined to ¥41.9B (△25.0%), and the Operating Income margin fell to 0.7%. By segment, Operating Income in the Pharmaceutical Wholesale Business was ¥35.3B (△11.0%), reflecting significant margin pressure. Regional Medical and Nursing Care Support posted a loss of △¥2.3B, while the Digital Business also posted a loss of △¥3.3B. Logistics posted Operating Income of ¥9.4B (+24.7%), partially offsetting the declines. Non-operating income included ¥2.8B in dividend income and ¥2.5B in equity-method investment gains, resulting in Ordinary Income of ¥50.7B (△12.3%). Profit Before Tax was ¥51.2B, and Net Income after deducting ¥17.3B in income taxes and other taxes was ¥33.8B (△10.6%). In conclusion, revenue increased while earnings declined.

Segment Analysis

The Pharmaceutical Wholesale Business expanded in scale, with revenue of ¥6,078.2B (96.7% of total revenue, +6.3% year on year), but Operating Income declined to ¥35.3B (△11.0%, margin: 0.6%), indicating continued margin pressure. Logistics generated Operating Income of ¥9.4B (+24.7%, margin: 6.5%) against revenue of ¥144.8B (+2.9%), contributing to earnings growth through its high profitability. Healthcare Product Development recorded revenue of ¥129.3B (+2.1%), but Operating Income declined sharply to ¥2.9B (△65.8%). Regional Medical and Nursing Care Support posted revenue of ¥227.2B (△1.7%) and fell into the red with an Operating Loss of △¥2.3B. The Digital Business also increased revenue to ¥8.1B (+33.3%), but its Operating Loss expanded to △¥3.3B. Based on the new medium-term management plan, segment classifications were changed from Q1, and the company is progressing with a transition toward a function-based management structure centered on fee-based businesses.

Key Financial Indicators

【Profitability】The Operating Income margin was 0.7% and the Net Income margin was 0.5%, both declining from the previous year (Operating Income margin of approximately 0.9%). The company continues to operate with a low-margin structure, with a gross profit margin of 6.9% and an SG&A ratio of 6.2%. ROE remained low at 0.8%. Basic EPS was ¥49.99, down △5.0% from ¥52.63 in the previous year.【Cash Flow Quality】Accounts receivable increased to ¥5,812.4B (+4.9%), inventories to ¥1,541.8B (+6.2%), and accounts payable to ¥7,006.2B (+5.2%), indicating expansion in working capital accompanying revenue growth. Trends in collection and inventory efficiency will determine the quality of earnings going forward.【Investment Efficiency】Goodwill was ¥34.4B, equivalent to only 0.8% of net assets, indicating limited impairment risk. Intangible assets were also relatively small at ¥150.0B.【Financial Soundness】The Equity Ratio was 34.8% (compared with 36.0% in the previous year). Against total assets of ¥11,956.8B and net assets of ¥4,158.9B, current assets of ¥9,181.2B and current liabilities of ¥7,532.6B resulted in a current ratio of approximately 121.9%, securing a minimum level of financial safety.

Cash Flow Analysis

As the cash flow statement has not been disclosed, funding trends can be assessed based on changes in the balance sheet. Cash and deposits increased to ¥1,214.2B, up ¥47.3B (+4.1%) year on year. At the same time, accounts receivable increased by ¥270.5B, inventories by ¥90.4B, and accounts payable by ¥348.6B, indicating an overall expansion in working capital and rising funding needs accompanying revenue growth. Given the settlement structure’s high dependence on accounts payable, and the simultaneous increases in inventory and accounts receivable, cash generation from operating activities is likely to grow more slowly than revenue in the current environment. In terms of capital investment, property, plant and equipment totaled ¥1,386.4B, remaining virtually unchanged from the previous year, suggesting that cash outflows from large-scale investments were limited.

Earnings Quality

The impact of extraordinary gains and losses on current-period earnings was extremely limited, with the earnings structure primarily based on recurring business activities. Extraordinary income of ¥0.7B (gain on the sale of fixed assets: ¥0.2B) and extraordinary losses of ¥0.2B (loss on the disposal and sale of fixed assets: ¥0.2B) were both immaterial, having only a very limited impact on Profit Before Tax of ¥51.2B. Of non-operating income of ¥9.9B, dividend income of ¥2.8B and other non-operating income of ¥3.5B were the main components, while equity-method investment gains of ¥2.5B also made a stable contribution. Comprehensive income was ¥32.2B, slightly below Net Income attributable to owners of the parent of ¥33.8B. The difference was attributable to negative valuation- and pension-related factors, including a △¥1.0B valuation difference on securities and a △¥0.8B adjustment related to retirement benefits. In assessing earnings quality, it is important that the decline in Operating Income was attributable not to temporary factors but to the structural factor of a lower gross profit margin.

Earnings Forecast and Guidance

For the full-year earnings forecast, Revenue of ¥25,630.0B (+3.1% year on year), Operating Income of ¥312.0B (△14.2%), and Ordinary Income of ¥343.0B (△13.7%) are planned. Q1 Revenue of ¥6,289.6B reached 24.5% of the full-year plan, representing generally steady progress. However, Q1 Operating Income of ¥41.9B amounted to only 13.4% of the full-year plan, falling significantly short of the simple one-quarter (25%) benchmark. This reflected the early deterioration in the Q1 gross profit margin and losses recorded by loss-making segments. Achievement of the full-year plan will depend on recovery in the gross profit margin and progress in cost efficiency during the second half of the fiscal year. No revisions were made to the earnings or dividend forecasts during the quarter.

Shareholder Returns

A 2-for-1 stock split is scheduled to take effect on October 1, 2026. Excluding the impact of the split, the forecast annual dividend for the fiscal year ending March 2027 is ¥120 per share (year-end dividend: ¥60). Using the company’s planned EPS of ¥184.81, the Payout Ratio is approximately 65%, indicating that the company’s shareholder return policy remains in place compared with the previous year’s actual dividend (¥50 per share in the same-period data for the previous year). However, the Payout Ratio is relatively high, and given the downward trend in Operating Income and the expansion of working capital, the trend in cash-generating capacity supporting earnings should be monitored.

Risk Factors

1. Margin Pressure Risk: The gross profit margin in the core Pharmaceutical Wholesale Business deteriorated from the previous year, and the Operating Income margin declined to 0.7% (approximately 0.9% in the previous year). If the pricing and rebate environment or product mix continues to change, profitability may deteriorate further.

2. Working Capital Expansion Risk: Working capital has expanded alongside revenue growth, with accounts receivable increasing by ¥270.5B, inventories by ¥90.4B, and accounts payable by ¥348.6B. If collection and inventory efficiency do not improve, cash-generating capacity may continue to lag behind the pace of revenue growth.

3. Risk of Delayed Monetization of New Businesses: Losses in the Digital Business (Operating Loss of △¥3.3B, △631.1% year on year) and Regional Medical and Nursing Care Support (△¥2.3B) have expanded, and the structure in which upfront investment burdens dilute the company-wide margin continues.

Industry Benchmark (For Reference; Company Research)

Industry Benchmark (trading)

Profitability and Returns

The company’s profitability is significantly below the industry median and ranks toward the lower end of the industry.

Growth and Capital Efficiency

The revenue growth rate exceeds the industry median, indicating that the pace of top-line expansion is relatively high.

※Source: Company research

Key Takeaways from the Results

1. Although Revenue increased by +6.1%, Operating Income declined by △25.0%. A defining feature of these results is that the structural factor of a lower gross profit margin is putting pressure on profitability.

2. The Logistics Business continued to grow, with Operating Income increasing by +24.7%, and is functioning as a source of earnings that offsets margin pressure in the core Pharmaceutical Wholesale Business. Meanwhile, the Digital Business and Regional Medical and Nursing Care Support posted losses, leaving monetization of the new businesses as an outstanding issue.

3. The Operating Income progress rate against the full-year plan was 13.4%, below the Revenue progress rate of 24.5%. Recovery in the gross profit margin and progress in expense efficiency during the second half will be key to achieving the full-year plan.

Theoretical Stock Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market stock price or a recommendation of any specific investment action.

Sensitivity: ¥4,973–¥5,263 at ±1% for the cost of equity, and ¥5,080–¥5,137 at ±0.1 for ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing discrepancy from the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-07 / This value does not forecast or guarantee the future stock price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, with consultation with professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Suzuken’s FY2027 Q1 result was operationally weak: revenue expanded, but a sharply lower pharmaceutical wholesale profit contribution drove a 25.0% decline in operating income. Consolidated revenue increased 6.1% year on year to JPY628.96bn. Gross profit rose only 0.2% to JPY43.35bn, materially lagging revenue growth. Accordingly, gross margin contracted by 40.5bp year on year to 6.9%. SG&A rose 3.9% to JPY39.16bn, slower than revenue but well ahead of gross-profit growth. The SG&A-to-sales ratio improved by 12.9bp to 6.2%, but this cost discipline was insufficient to offset the gross-margin pressure. Operating income fell to JPY4.19bn and the operating margin compressed by 27.6bp to 0.7%. Ordinary income declined by a narrower 12.3% to JPY5.07bn, supported by a JPY0.69bn increase in non-operating income. Net income attributable to owners fell 10.6% to JPY3.38bn, equivalent to EPS of JPY49.99. The effective tax rate was 33.8%, leaving a tax burden of 0.660. The annualized DuPont ROE was 3.2%, reflecting a very thin 0.5% net margin despite annualized asset turnover of 2.104x and financial leverage of 2.88x. The balance sheet remains liquid on a current-ratio basis, with a 121.9% current ratio and a 101.4% quick ratio. However, the business continues to carry substantial operating working capital, including JPY581.24bn of trade receivables and JPY700.62bn of trade payables. Management’s full-year guidance implies that Q1 operating-income progress is only 13.4%, far below the standard 25% quarterly run rate. The primary forward implication is that the company needs a material recovery in wholesale gross-profit generation and/or seasonal profit concentration in subsequent quarters to achieve the unchanged full-year plan.

Profitability Analysis

Annualized DuPont analysis decomposes ROE of 3.2% into a 0.5% net profit margin, 2.104x asset turnover, and 2.88x financial leverage. The limiting factor is decisively margin rather than asset utilization: the company generates high sales volume relative to assets, but retains only a small portion of sales as earnings. Gross margin fell from 7.3% in the prior-year quarter to 6.9%, a 40.5bp contraction, and operating margin declined from 0.9% to 0.7%, a 27.6bp contraction. Gross profit increased just JPY0.08bn while SG&A increased JPY1.48bn, explaining the JPY1.40bn reduction in operating income. This is a negative operating-leverage outcome because revenue grew JPY36.09bn while the gross-profit pool was essentially flat. The low 0.7% EBIT margin is a quality alert and is structurally important: even modest changes in procurement terms, pricing, product mix, logistics costs, or reimbursement conditions can have a large effect on earnings. The 6.9% gross margin is also flagged as low, although thin gross margins are characteristic of pharmaceutical wholesaling and therefore should be assessed relative to this distribution-led business model rather than against broad-market margin benchmarks. Financial leverage of 2.88x supports reported ROE but does not offset the weak underlying return on assets. Interest coverage of 419.0x is very strong, as interest expense was only JPY0.01bn, so leverage is principally an operating-balance-sheet feature rather than a material funding-cost burden. The interest burden of 1.222 reflects profit before tax exceeding EBIT through non-operating income, rather than financial stress. Non-operating income included JPY0.28bn of dividend income, JPY0.04bn of interest income and JPY0.25bn of equity-method earnings; these items supported ordinary income but do not resolve the deterioration in operating profitability.

Growth Assessment

Revenue growth of 6.1% was driven primarily by the pharmaceutical wholesale business, whose external sales increased 6.5% to JPY597.16bn. The pharmaceutical wholesale business remains the core business by operating-income contribution, producing JPY3.53bn of segment profit, or approximately 83% of aggregate segment profit. However, its segment profit declined 11.0% year on year despite sales growth, indicating that revenue growth has not translated into commensurate economic value. Logistics was the strongest reported segment operationally, with external revenue up 0.4% to JPY5.24bn and segment profit up 24.7% to JPY0.94bn. Healthcare product development recorded external revenue of JPY2.66bn, down 10.0%, while segment profit fell 65.8% to JPY0.29bn. Regional medical and nursing-care support reported external revenue of JPY22.71bn, down 1.7%, and swung to a JPY0.23bn segment loss from a JPY0.02bn profit. Digital business remained loss-making, with a JPY0.33bn segment loss versus a JPY0.05bn loss a year earlier, notwithstanding external revenue growth to JPY0.28bn. The segment reorganization under the new medium-term plan is intended to manage digital, logistics and other functional capabilities as independent businesses, which may improve accountability for fee-based growth initiatives. The full-year sales forecast is JPY2,563.0bn, and Q1 sales progress of 24.5% is broadly in line with the standard 25% pace. In contrast, Q1 operating-income progress is 13.4% against the JPY31.20bn forecast, 11.6 percentage points below the standard pace. Ordinary-income progress is 14.8% against the JPY34.30bn forecast, while net-income progress is 13.5% against the JPY25.00bn forecast. The unchanged guidance therefore requires a substantial earnings acceleration after Q1. The forecast itself calls for 3.1% sales growth but a 14.2% operating-income decline for the full year, indicating management does not expect a full restoration of margin performance within the fiscal year.

Financial Health

Liquidity is adequate, with current assets of JPY918.12bn exceeding current liabilities of JPY753.26bn and producing working capital of JPY164.86bn. The current ratio of 121.9% is above 1.0x and therefore does not indicate an immediate liquidity shortfall, although it remains below the 1.5x level often considered more conservative. The quick ratio of 101.4% exceeds 1.0x, indicating that liquid current assets can broadly cover current obligations without reliance on inventory liquidation. Cash and deposits were JPY121.42bn, equivalent to 10.2% of total assets. Trade receivables were JPY581.24bn, or 48.6% of assets, while inventories were JPY154.18bn, or 12.9% of assets. Trade payables of JPY700.62bn fund a substantial share of the working-capital cycle and are broadly aligned with the company’s pharmaceutical distribution model. Current liabilities rose JPY40.21bn year on year, broadly matching the JPY41.95bn increase in current assets; this indicates no material deterioration in the current ratio. Total equity was essentially stable year on year at JPY415.89bn, while total assets rose JPY39.92bn. D/E was 1.88x, elevated but below the 2.0x threshold that would warrant an explicit aggressive-leverage warning under the stated benchmark. Non-current liabilities were limited at JPY26.54bn, so the balance sheet does not exhibit a material long-term debt maturity mismatch. Goodwill was JPY3.44bn, only 0.8% of equity and 0.3% of assets, indicating that balance-sheet value is not materially dependent on acquisition goodwill. Intangible assets represented 1.3% of assets, also a low concentration. Provision for bonuses declined by JPY5.69bn year on year to JPY3.89bn, a movement exceeding JPY5.0bn; this should be monitored in the context of compensation accrual timing because it affects short-term liabilities and working-capital movements.

Notable B/S Changes

Provision for bonuses: -JPY5.69bn (-59.4%) year on year to JPY3.89bn - a material short-term-liability movement that should be monitored alongside compensation accrual timing and working-capital trends.

Cash Flow Quality

Dividend Sustainability

The company plans a two-for-one stock split effective 1 October 2026. The FY2027 forecast, before reflecting the stock split, implies an annual dividend of JPY120 per share, comprising a JPY60 year-end dividend and the corresponding interim amount. Against forecast EPS of JPY184.81, this implies a dividend payout ratio of approximately 64.9%. This is moderately above the stated 60% sustainability benchmark, but remains below a 100% payout level. The dividend outlook therefore depends on management delivering a recovery from Q1’s weak 13.5% net-income progress toward the full-year forecast. The absence of a dividend forecast revision alongside unchanged earnings guidance indicates that management currently intends to maintain the indicated shareholder distribution framework. The planned stock split changes per-share presentation but does not, by itself, change the aggregate economic distribution.

Risk Assessment

Business risks include Pharmaceutical wholesale margin risk is the highest-priority operating risk: core pharmaceutical wholesale revenue rose 6.5%, but segment profit fell 11.0%, demonstrating sensitivity to pricing, purchase terms, product mix and distribution costs., The 0.7% EBIT margin and 6.9% gross margin are both quality alerts. Thin margins are typical of distribution businesses, but they leave limited protection against reimbursement-price revisions, supplier negotiations, logistics inflation and competitive pricing., The regional medical and nursing-care support segment moved to a JPY0.23bn loss, while digital business losses widened to JPY0.33bn. Continued investment without a clear route to profitability could dilute consolidated returns., Receivable collection risk is elevated by the 84-day DSO quality alert. In a high-volume wholesaler, this may partly reflect ordinary customer settlement practices, but it increases sensitivity to counterparty credit conditions and working-capital funding requirements., Industry-specific risk includes policy and reimbursement changes in Japan’s healthcare system, which can alter pharmaceutical distribution economics even where shipment volumes remain resilient..

Financial risks include D/E of 1.88x is elevated, although below the 2.0x aggressive-leverage threshold and accompanied by very strong 419.0x interest coverage., The company relies heavily on the operating working-capital cycle: receivables of JPY581.24bn and inventories of JPY154.18bn are funded in significant part by JPY700.62bn of trade payables., Annualized ROIC of 3.8% is below the 5% warning threshold, indicating that current earnings returns are low relative to the capital committed to the business., Q1 operating-income progress of 13.4% versus the full-year plan creates execution risk, particularly because the full-year forecast already anticipates a 14.2% year-on-year decline in operating income..

Key concerns include Margin recovery in the pharmaceutical wholesale core business is the most important determinant of whether sales growth can translate into earnings growth., The JPY0.69bn year-on-year improvement in non-operating income softened the decline in ordinary income, but operating income still fell JPY1.40bn; the investment case is therefore more exposed to recurring operating performance than headline ordinary income suggests., Monitor DSO, trade receivables, inventory levels and trade payables together for signs that revenue growth is requiring disproportionately more working capital., Monitor the profitability trajectory of digital business and regional medical and nursing-care support following the new segment structure..

Investment Implications

Key takeaways include Q1 revenue growth was solid at 6.1%, but earnings conversion was weak, with operating income down 25.0%., The core pharmaceutical wholesale segment generated most segment profit but saw profit decline despite higher sales., Annualized ROE of 3.2% and annualized ROIC of 3.8% indicate low capital efficiency, with weak margins as the principal constraint., Liquidity is adequate and funding costs are immaterial, but the operating model requires close management of large receivable, inventory and payable balances., Full-year guidance requires a meaningful improvement in quarterly profitability after Q1..

Metrics to watch include Pharmaceutical wholesale segment profit and segment margin, Consolidated gross margin and operating margin, Operating-income progress versus the JPY31.20bn full-year forecast, DSO, trade receivables, inventories and trade payables, Digital business and regional medical and nursing-care support segment profitability, Annualized ROIC and annualized ROE.

Regarding relative positioning, Suzuken exhibits the profile of a high-turnover healthcare distributor: asset turnover is comparatively strong, liquidity is adequate and interest coverage is exceptionally high, but earnings returns are constrained by structurally thin margins. Relative performance will depend principally on the company’s ability to improve gross-profit capture and monetize fee-based functional services under its next-generation wholesale strategy.